ovcar3 human ovarian cancer cells Search Results


human cancer cell line ovcar-3  (China Center for Type Culture Collection)
90
China Center for Type Culture Collection human cancer cell line ovcar-3
Human Cancer Cell Line Ovcar 3, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cancer cell line ovcar-3/product/China Center for Type Culture Collection
Average 90 stars, based on 1 article reviews
human cancer cell line ovcar-3 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ovcar3  (ScienCell)
90
ScienCell ovcar3
Analyses of survival-related FRGs in OC. (A) Ferroptosis pivot genes, namely, SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in platinum-resistant tissues (R1-R3) and platinum-sensitive tissues (S1-S3). (B) SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in ovarian cell lines <t>(OVCAR3</t> and SKOV3) and platinum-resistant OC cell lines (OVCAR3-CDDP and SKOV3-CDDP). (C) Cell viability assays under cisplatin treatment; SKOV3/CDDP showed higher cisplatin tolerance, representing the resistance phenotype. Cells were treated with cisplatin (2.2 μg/ml for SKOV3 and 6.9 μg/ml for SKOV3-CDDP) in the absence or presence of erastin (10 μM), RSL3 (0.1 μM), and NAC (1 mM) for 24 h and cell viability. (D) Glutathione (GSH) (E) and lipid peroxidation (MDA) assays (F) were performed. (G) XCT, GPX4, and β-actin protein expression in SKOV3 (i) and SKOV3-CDDP (ii) under the abovementioned treatment. Error bars represent the standard deviation (s.d.) of triplicate measurements. * p < 0.05 and ** p < 0.01.
Ovcar3, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovcar3/product/ScienCell
Average 90 stars, based on 1 article reviews
ovcar3 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human ovarian adenocarcinoma ovcar-3 cancer cells  (Janvier Labs)
90
Janvier Labs human ovarian adenocarcinoma ovcar-3 cancer cells
Analyses of survival-related FRGs in OC. (A) Ferroptosis pivot genes, namely, SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in platinum-resistant tissues (R1-R3) and platinum-sensitive tissues (S1-S3). (B) SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in ovarian cell lines <t>(OVCAR3</t> and SKOV3) and platinum-resistant OC cell lines (OVCAR3-CDDP and SKOV3-CDDP). (C) Cell viability assays under cisplatin treatment; SKOV3/CDDP showed higher cisplatin tolerance, representing the resistance phenotype. Cells were treated with cisplatin (2.2 μg/ml for SKOV3 and 6.9 μg/ml for SKOV3-CDDP) in the absence or presence of erastin (10 μM), RSL3 (0.1 μM), and NAC (1 mM) for 24 h and cell viability. (D) Glutathione (GSH) (E) and lipid peroxidation (MDA) assays (F) were performed. (G) XCT, GPX4, and β-actin protein expression in SKOV3 (i) and SKOV3-CDDP (ii) under the abovementioned treatment. Error bars represent the standard deviation (s.d.) of triplicate measurements. * p < 0.05 and ** p < 0.01.
Human Ovarian Adenocarcinoma Ovcar 3 Cancer Cells, supplied by Janvier Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ovarian adenocarcinoma ovcar-3 cancer cells/product/Janvier Labs
Average 90 stars, based on 1 article reviews
human ovarian adenocarcinoma ovcar-3 cancer cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ovcar3 human cell line-derived ovarian cancer model  (Crown Bioscience)
90
Crown Bioscience ovcar3 human cell line-derived ovarian cancer model
Analyses of survival-related FRGs in OC. (A) Ferroptosis pivot genes, namely, SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in platinum-resistant tissues (R1-R3) and platinum-sensitive tissues (S1-S3). (B) SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in ovarian cell lines <t>(OVCAR3</t> and SKOV3) and platinum-resistant OC cell lines (OVCAR3-CDDP and SKOV3-CDDP). (C) Cell viability assays under cisplatin treatment; SKOV3/CDDP showed higher cisplatin tolerance, representing the resistance phenotype. Cells were treated with cisplatin (2.2 μg/ml for SKOV3 and 6.9 μg/ml for SKOV3-CDDP) in the absence or presence of erastin (10 μM), RSL3 (0.1 μM), and NAC (1 mM) for 24 h and cell viability. (D) Glutathione (GSH) (E) and lipid peroxidation (MDA) assays (F) were performed. (G) XCT, GPX4, and β-actin protein expression in SKOV3 (i) and SKOV3-CDDP (ii) under the abovementioned treatment. Error bars represent the standard deviation (s.d.) of triplicate measurements. * p < 0.05 and ** p < 0.01.
Ovcar3 Human Cell Line Derived Ovarian Cancer Model, supplied by Crown Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovcar3 human cell line-derived ovarian cancer model/product/Crown Bioscience
Average 90 stars, based on 1 article reviews
ovcar3 human cell line-derived ovarian cancer model - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ovcar-3 luciferase-expressing human ovarian cancer cells ovcar-3-luc  (Pharmaron Inc)
90
Pharmaron Inc ovcar-3 luciferase-expressing human ovarian cancer cells ovcar-3-luc
Analyses of survival-related FRGs in OC. (A) Ferroptosis pivot genes, namely, SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in platinum-resistant tissues (R1-R3) and platinum-sensitive tissues (S1-S3). (B) SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in ovarian cell lines <t>(OVCAR3</t> and SKOV3) and platinum-resistant OC cell lines (OVCAR3-CDDP and SKOV3-CDDP). (C) Cell viability assays under cisplatin treatment; SKOV3/CDDP showed higher cisplatin tolerance, representing the resistance phenotype. Cells were treated with cisplatin (2.2 μg/ml for SKOV3 and 6.9 μg/ml for SKOV3-CDDP) in the absence or presence of erastin (10 μM), RSL3 (0.1 μM), and NAC (1 mM) for 24 h and cell viability. (D) Glutathione (GSH) (E) and lipid peroxidation (MDA) assays (F) were performed. (G) XCT, GPX4, and β-actin protein expression in SKOV3 (i) and SKOV3-CDDP (ii) under the abovementioned treatment. Error bars represent the standard deviation (s.d.) of triplicate measurements. * p < 0.05 and ** p < 0.01.
Ovcar 3 Luciferase Expressing Human Ovarian Cancer Cells Ovcar 3 Luc, supplied by Pharmaron Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovcar-3 luciferase-expressing human ovarian cancer cells ovcar-3-luc/product/Pharmaron Inc
Average 90 stars, based on 1 article reviews
ovcar-3 luciferase-expressing human ovarian cancer cells ovcar-3-luc - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ovcar-3 human ovarian cancer cells  (Nanjing KeyGen Biotech Co Ltd)
90
Nanjing KeyGen Biotech Co Ltd ovcar-3 human ovarian cancer cells
Analyses of survival-related FRGs in OC. (A) Ferroptosis pivot genes, namely, SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in platinum-resistant tissues (R1-R3) and platinum-sensitive tissues (S1-S3). (B) SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in ovarian cell lines <t>(OVCAR3</t> and SKOV3) and platinum-resistant OC cell lines (OVCAR3-CDDP and SKOV3-CDDP). (C) Cell viability assays under cisplatin treatment; SKOV3/CDDP showed higher cisplatin tolerance, representing the resistance phenotype. Cells were treated with cisplatin (2.2 μg/ml for SKOV3 and 6.9 μg/ml for SKOV3-CDDP) in the absence or presence of erastin (10 μM), RSL3 (0.1 μM), and NAC (1 mM) for 24 h and cell viability. (D) Glutathione (GSH) (E) and lipid peroxidation (MDA) assays (F) were performed. (G) XCT, GPX4, and β-actin protein expression in SKOV3 (i) and SKOV3-CDDP (ii) under the abovementioned treatment. Error bars represent the standard deviation (s.d.) of triplicate measurements. * p < 0.05 and ** p < 0.01.
Ovcar 3 Human Ovarian Cancer Cells, supplied by Nanjing KeyGen Biotech Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovcar-3 human ovarian cancer cells/product/Nanjing KeyGen Biotech Co Ltd
Average 90 stars, based on 1 article reviews
ovcar-3 human ovarian cancer cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human ovarian cancer cell line ovcar 3  (Cedarlane)
94
Cedarlane human ovarian cancer cell line ovcar 3
Analyses of survival-related FRGs in OC. (A) Ferroptosis pivot genes, namely, SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in platinum-resistant tissues (R1-R3) and platinum-sensitive tissues (S1-S3). (B) SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in ovarian cell lines <t>(OVCAR3</t> and SKOV3) and platinum-resistant OC cell lines (OVCAR3-CDDP and SKOV3-CDDP). (C) Cell viability assays under cisplatin treatment; SKOV3/CDDP showed higher cisplatin tolerance, representing the resistance phenotype. Cells were treated with cisplatin (2.2 μg/ml for SKOV3 and 6.9 μg/ml for SKOV3-CDDP) in the absence or presence of erastin (10 μM), RSL3 (0.1 μM), and NAC (1 mM) for 24 h and cell viability. (D) Glutathione (GSH) (E) and lipid peroxidation (MDA) assays (F) were performed. (G) XCT, GPX4, and β-actin protein expression in SKOV3 (i) and SKOV3-CDDP (ii) under the abovementioned treatment. Error bars represent the standard deviation (s.d.) of triplicate measurements. * p < 0.05 and ** p < 0.01.
Human Ovarian Cancer Cell Line Ovcar 3, supplied by Cedarlane, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ovarian cancer cell line ovcar 3/product/Cedarlane
Average 94 stars, based on 1 article reviews
human ovarian cancer cell line ovcar 3 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
ovcar-3-rfp human ovarian cancer cell line  (Anticancer Inc)
90
Anticancer Inc ovcar-3-rfp human ovarian cancer cell line
Analyses of survival-related FRGs in OC. (A) Ferroptosis pivot genes, namely, SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in platinum-resistant tissues (R1-R3) and platinum-sensitive tissues (S1-S3). (B) SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in ovarian cell lines <t>(OVCAR3</t> and SKOV3) and platinum-resistant OC cell lines (OVCAR3-CDDP and SKOV3-CDDP). (C) Cell viability assays under cisplatin treatment; SKOV3/CDDP showed higher cisplatin tolerance, representing the resistance phenotype. Cells were treated with cisplatin (2.2 μg/ml for SKOV3 and 6.9 μg/ml for SKOV3-CDDP) in the absence or presence of erastin (10 μM), RSL3 (0.1 μM), and NAC (1 mM) for 24 h and cell viability. (D) Glutathione (GSH) (E) and lipid peroxidation (MDA) assays (F) were performed. (G) XCT, GPX4, and β-actin protein expression in SKOV3 (i) and SKOV3-CDDP (ii) under the abovementioned treatment. Error bars represent the standard deviation (s.d.) of triplicate measurements. * p < 0.05 and ** p < 0.01.
Ovcar 3 Rfp Human Ovarian Cancer Cell Line, supplied by Anticancer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ovcar-3-rfp human ovarian cancer cell line/product/Anticancer Inc
Average 90 stars, based on 1 article reviews
ovcar-3-rfp human ovarian cancer cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human ovarian cancer cell line ovcar-3 #kg040  (Keygen Biotech)
90
Keygen Biotech human ovarian cancer cell line ovcar-3 #kg040
Analyses of survival-related FRGs in OC. (A) Ferroptosis pivot genes, namely, SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in platinum-resistant tissues (R1-R3) and platinum-sensitive tissues (S1-S3). (B) SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in ovarian cell lines <t>(OVCAR3</t> and SKOV3) and platinum-resistant OC cell lines (OVCAR3-CDDP and SKOV3-CDDP). (C) Cell viability assays under cisplatin treatment; SKOV3/CDDP showed higher cisplatin tolerance, representing the resistance phenotype. Cells were treated with cisplatin (2.2 μg/ml for SKOV3 and 6.9 μg/ml for SKOV3-CDDP) in the absence or presence of erastin (10 μM), RSL3 (0.1 μM), and NAC (1 mM) for 24 h and cell viability. (D) Glutathione (GSH) (E) and lipid peroxidation (MDA) assays (F) were performed. (G) XCT, GPX4, and β-actin protein expression in SKOV3 (i) and SKOV3-CDDP (ii) under the abovementioned treatment. Error bars represent the standard deviation (s.d.) of triplicate measurements. * p < 0.05 and ** p < 0.01.
Human Ovarian Cancer Cell Line Ovcar 3 #Kg040, supplied by Keygen Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ovarian cancer cell line ovcar-3 #kg040/product/Keygen Biotech
Average 90 stars, based on 1 article reviews
human ovarian cancer cell line ovcar-3 #kg040 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nih:ovcar-3 human ovarian cancer cell lines  (Korean Cell Line Bank)
90
Korean Cell Line Bank nih:ovcar-3 human ovarian cancer cell lines
Analyses of survival-related FRGs in OC. (A) Ferroptosis pivot genes, namely, SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in platinum-resistant tissues (R1-R3) and platinum-sensitive tissues (S1-S3). (B) SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in ovarian cell lines <t>(OVCAR3</t> and SKOV3) and platinum-resistant OC cell lines (OVCAR3-CDDP and SKOV3-CDDP). (C) Cell viability assays under cisplatin treatment; SKOV3/CDDP showed higher cisplatin tolerance, representing the resistance phenotype. Cells were treated with cisplatin (2.2 μg/ml for SKOV3 and 6.9 μg/ml for SKOV3-CDDP) in the absence or presence of erastin (10 μM), RSL3 (0.1 μM), and NAC (1 mM) for 24 h and cell viability. (D) Glutathione (GSH) (E) and lipid peroxidation (MDA) assays (F) were performed. (G) XCT, GPX4, and β-actin protein expression in SKOV3 (i) and SKOV3-CDDP (ii) under the abovementioned treatment. Error bars represent the standard deviation (s.d.) of triplicate measurements. * p < 0.05 and ** p < 0.01.
Nih:Ovcar 3 Human Ovarian Cancer Cell Lines, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nih:ovcar-3 human ovarian cancer cell lines/product/Korean Cell Line Bank
Average 90 stars, based on 1 article reviews
nih:ovcar-3 human ovarian cancer cell lines - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human ovarian cancer ovcar3 cells  (Beyotime)
90
Beyotime human ovarian cancer ovcar3 cells
Analyses of survival-related FRGs in OC. (A) Ferroptosis pivot genes, namely, SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in platinum-resistant tissues (R1-R3) and platinum-sensitive tissues (S1-S3). (B) SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in ovarian cell lines <t>(OVCAR3</t> and SKOV3) and platinum-resistant OC cell lines (OVCAR3-CDDP and SKOV3-CDDP). (C) Cell viability assays under cisplatin treatment; SKOV3/CDDP showed higher cisplatin tolerance, representing the resistance phenotype. Cells were treated with cisplatin (2.2 μg/ml for SKOV3 and 6.9 μg/ml for SKOV3-CDDP) in the absence or presence of erastin (10 μM), RSL3 (0.1 μM), and NAC (1 mM) for 24 h and cell viability. (D) Glutathione (GSH) (E) and lipid peroxidation (MDA) assays (F) were performed. (G) XCT, GPX4, and β-actin protein expression in SKOV3 (i) and SKOV3-CDDP (ii) under the abovementioned treatment. Error bars represent the standard deviation (s.d.) of triplicate measurements. * p < 0.05 and ** p < 0.01.
Human Ovarian Cancer Ovcar3 Cells, supplied by Beyotime, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ovarian cancer ovcar3 cells/product/Beyotime
Average 90 stars, based on 1 article reviews
human ovarian cancer ovcar3 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Analyses of survival-related FRGs in OC. (A) Ferroptosis pivot genes, namely, SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in platinum-resistant tissues (R1-R3) and platinum-sensitive tissues (S1-S3). (B) SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in ovarian cell lines (OVCAR3 and SKOV3) and platinum-resistant OC cell lines (OVCAR3-CDDP and SKOV3-CDDP). (C) Cell viability assays under cisplatin treatment; SKOV3/CDDP showed higher cisplatin tolerance, representing the resistance phenotype. Cells were treated with cisplatin (2.2 μg/ml for SKOV3 and 6.9 μg/ml for SKOV3-CDDP) in the absence or presence of erastin (10 μM), RSL3 (0.1 μM), and NAC (1 mM) for 24 h and cell viability. (D) Glutathione (GSH) (E) and lipid peroxidation (MDA) assays (F) were performed. (G) XCT, GPX4, and β-actin protein expression in SKOV3 (i) and SKOV3-CDDP (ii) under the abovementioned treatment. Error bars represent the standard deviation (s.d.) of triplicate measurements. * p < 0.05 and ** p < 0.01.

Journal: Frontiers in Genetics

Article Title: Comprehensive Analysis of the Tumor Microenvironment and Ferroptosis-Related Genes Predict Prognosis with Ovarian Cancer

doi: 10.3389/fgene.2021.774400

Figure Lengend Snippet: Analyses of survival-related FRGs in OC. (A) Ferroptosis pivot genes, namely, SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in platinum-resistant tissues (R1-R3) and platinum-sensitive tissues (S1-S3). (B) SLC7A5, ACSL4, XCT, GPX4, and β-actin protein expression in ovarian cell lines (OVCAR3 and SKOV3) and platinum-resistant OC cell lines (OVCAR3-CDDP and SKOV3-CDDP). (C) Cell viability assays under cisplatin treatment; SKOV3/CDDP showed higher cisplatin tolerance, representing the resistance phenotype. Cells were treated with cisplatin (2.2 μg/ml for SKOV3 and 6.9 μg/ml for SKOV3-CDDP) in the absence or presence of erastin (10 μM), RSL3 (0.1 μM), and NAC (1 mM) for 24 h and cell viability. (D) Glutathione (GSH) (E) and lipid peroxidation (MDA) assays (F) were performed. (G) XCT, GPX4, and β-actin protein expression in SKOV3 (i) and SKOV3-CDDP (ii) under the abovementioned treatment. Error bars represent the standard deviation (s.d.) of triplicate measurements. * p < 0.05 and ** p < 0.01.

Article Snippet: OC cell lines, namely, OVCAR3 and SKOV3 were obtained from Sciencell (California, United States) and maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum.

Techniques: Expressing, Standard Deviation